Subject(s)
Antibiotics, Antitubercular/adverse effects , Rifabutin/adverse effects , Rifampin/therapeutic use , Stevens-Johnson Syndrome/drug therapy , Stevens-Johnson Syndrome/etiology , Cross Reactions/immunology , Humans , Immunoglobulin E/immunology , Male , Middle Aged , Rifampin/administration & dosage , Treatment OutcomeABSTRACT
Our current recommendations for diagnosing and treating primary mast cell (MC) activation syndrome make use of the latest studies and consensus guidelines for clinically recognizing systemic anaphylaxis in real time, regardless of whether allergen-triggered or other pathways are involved; our current understanding of the biomarkers secreted by activated MCs that best discriminate this disorder from other conditions; and the therapeutic drugs that might selectively affect those mediators or MCs themselves. Finding familial or somatic mutations of genes that cause MCs to be hyperactivatable would extend our diagnostic tools and potentially indicate new therapeutic interventions, targeting either the mutated gene product or the associated molecular pathway. In conclusion, we trust that the clinical, laboratory, and therapeutic criteria for primary MC activation syndromes described herein will provide clinicians with practical criteria of sufficient sensitivity and specificity to diagnose most cases without overdiagnosing the disorder in patients who likely have other conditions.
Subject(s)
Mastocytosis/diagnosis , Mastocytosis/therapy , HumansSubject(s)
Antibodies, Monoclonal/administration & dosage , Immunotherapy/methods , Mevalonate Kinase Deficiency/diagnosis , Phosphotransferases (Alcohol Group Acceptor)/genetics , Adult , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal, Humanized , DNA Mutational Analysis , Delayed Diagnosis , Female , Humans , Interleukin-1beta/immunology , Mevalonate Kinase Deficiency/immunology , Mevalonate Kinase Deficiency/therapy , Mutation/geneticsABSTRACT
The treatment options for patients with sarcoidosis are presently limited, and it is unclear which treatments are most effective for any given patient. We have identified a sarcoidosis phenotype characterized by CD4(+) lymphopenia and resistance to conventional immunosuppressants, such as corticosteroids and methotrexate. Based on recent reports linking tumor necrosis factor (TNF)-alpha to regulatory T-cell (Treg) dysfunction, we hypothesized that sarcoidosis-associated CD4(+) lymphopenia would resolve with anti-TNFalpha treatment. Five consecutive patients with CD4(+) lymphopenia were treated with a chimeric anti-TNFalpha antibody (infliximab). Clinical disease manifestations and peripheral blood T-cell subsets were assessed before and after infliximab treatment. All patients experienced significant increases in absolute peripheral blood lymphocyte and CD4(+) T-cell counts and demonstrated improvement in clinical disease manifestations in response to infliximab. No change in the distribution of T-cell subsets was noted. The presence of CD4(+) lymphopenia identifies a distinct sarcoidosis phenotype that is particularly responsive to anti-TNFalpha therapy.
